Background Since venous thromboembolism (VTE) is one of the causes of maternal mortality, several guidelines recommend prophylaxis using low molecular weight heparin for women in high-risk groups. The number of large population-based studies examining predictors for VTE has been limited, and there has been no study based on a Japanese population. Objective Our objective was to examine VTE risk factor during the pregnancy and post-partum period. Materials and Methods A nationwide birth cohort study known as the 'Japan Environment and Children's Study (JECS)' was conducted by the Ministry of the Environment. The subjects consisted of 103,070 pregnancies recruited by the JECS between January 2011 and March 2014. Pregnant women completed the questionnaires during the first and second/ third trimester. Their medical records were transcribed by physicians or research coordinators at registration, just after delivery and at 1 month after delivery. Results The frequency of VTE was 7.5 per 10,000 pregnancies (77 of 103,070) during the pregnancy and post-partum period. After the adjustment of multiple covariates for each factor, endometriosis and recurrent pregnancy loss (RPL) were identified as novel independent risk factors for VTE. Adjusted odds ratios were as follows: 2.70 (95% confidence interval, 1.21-6.00) for endometriosis and 6.13 (2.48-15.16) for RPL. Threatened abortion, threatened pre-term birth, pre-term birth and caesarean section were ascertained to be risk factors for VTE. Conclusion Careful attention should be given to novel predictors, such as endometriosis and a history of RPL, to prevent VTE during the pregnancy and post-partum period.
Introduction
It is well known that pregnancy and puerperium is associated with venous thromboembolism (VTE). The frequency of post-partum VTE was reported to be 7.2 per 10,000 deliveries in an English cohort registered between 1997 and 2014 and 7.9 in a Swedish cohort registered between 2005 and 2011. 1 Since VTE is one of the causes of maternal mortality, several guidelines recommend prophylaxis using low molecular weight heparin (LMWH) for women in the high-risk group. 2, 3 The strongest risk factor is a previous episode. 2, 3 The recurrence rate of withholding heparin was 2.4% in 125 pregnant women with previous VTE, 0% in 44 women without thrombophilia and 5.9% in 51 women with thrombophilia and/or previous episode of idiopathic thrombosis. 4 Pregnant women who have had two or more episodes, one episode plus thrombophilia associated with anti-phospholipid antibodies, protein C (PC), protein S (PS) or an antithrombin (AT) deficiency, and one episode plus a history of VTE in a first-degree relative are all included in the highest risk group. 2, 3 The second highest risk group includes women with an isolated episode during bed rest, dehydration and surgery, thrombophilia or with a complication such as heart disease, lung disease, systemic lupus erythematosus (SLE), cancer, inflammatory bowel disease or nephrotic syndrome. 2, 3, 5 The third highest group includes women with an age 3 35 years, a body mass index (BMI) of > 30 kg/m 2 , a smoker, parity 3 3, a systemic infection, gross varicose veins, paraplegia, pre-eclampsia, hyperemesis, ovarian hyperstimulation syndrome, multiple pregnancies, use of artificial reproductive technology, caesarean section and post-partum haemorrhage. 2, 3, 5 Accordingly, LMWH is recommended for pregnant women with three or more of these risk factors.
However, both the Royal College of Obstetricians and Gynaecologists (RCOG) guidelines and the American College of Chest Physicians (ACCP) evidence-based clinical practice guidelines have recommended that LMWH use should be decided upon after discussion between two or more doctors in the case of the second and third highest risk groups since these guidelines were based on expert opinion due to limited evidence concerning the effect of thromboprophylaxis during pregnancy. 2, 3, 6 The Japan Society of Obstetrics and Gynecology (JSOG) drew up guidelines in 2014 that conformed to the RCOG and ACCP guidelines due to a lack of evidence in Japan. 7 Before April 2014, thromboprophylaxis was performed according to the previous guidelines, under which an episode of VTE, thrombophilia, age 3 35 years, a caesarean section and obesity were considered to be risk factors for Japanese women. 8 For the highest risk group, low dose unfractionated heparin was recommended for women with a past episode of VTE or thrombophilia who underwent a caesarean section during the post-partum period. Unfractionated heparin or intermittent pneumatic compression was recommended for older obese women after caesarean section or for women with an episode of VTE or thrombophilia after vaginal delivery in the high-risk group. There has been no study of VTE risk factors in Japanese women during the pregnancy and post-partum period. Therefore, it was considered necessary to examine these factors because the frequency of VTE is smaller in Japanese populations than in Caucasian population and the frequency of thrombophilia depends on race. 9 We have conducted a nationwide population-based birth cohort study known as the 'Japan Environment and Children's Study (JECS)', a project planned by the Ministry of the Environment, Government of Japan. [10] [11] [12] [13] [14] The study subjects consisted of 104,102 registered children or foetuses recruited during the first 3 years of the JECS, and the babies are now being followed up for 13 years mainly to examine the influence of the environment on the foetus. This is the first birth cohort used to examine the frequency of VTE and to determine VTE risk factors during the pregnancy and post-partum period in a Japanese population.
Materials and Methods

Study Design and Participants
Pregnant women were recruited by the JECS between January 2011 and March 2014. Eligibility criteria for expectant mothers were as follows: that they (1) resided at the time of recruitment in any of the study areas selected by 15 regional JECS centres located countrywide; (2) had an expected delivery date after August 1, 2011; and (3) were capable of comprehending the Japanese language and completing the self-administered questionnaire. [10] [11] [12] [13] [14] The sample size has been calculated in the JECS protocol by the Ministry of the Environment. 15 In principle, pregnant women completed the questionnaires during the first (MT1) and second/third trimester (MT2). Their medical records were transcribed by physicians or research coordinators at registration (DrT1), just after delivery (Dr0m) and at 1 month after delivery (Dr1m).
This study was based on the jecs-ag-20160424 dataset, which includes 104,102 registered children (foetuses and embryos), and was released restrictively to all concerned in June 2016. The second and third children of multiple pregnancies were excluded and these numbered 1,003 (0.96%). Twenty-nine participants (0.03%) withdrew their consent completely. Finally, 103,070 pregnancies were included in the main analysis. The mean (standard deviation [SD]) age at registration was 30.7 (5.1) years. The mean (SD) gestational weeks at registration was 14.0 (5.7) weeks. The JECS population has been recognized as representative of the pregnant women in Japan. 11 The JECS protocol was reviewed and approved by the Ministry of the Environment's Institutional Review Board on Epidemiological Studies and by the Ethics Committees of all participating institutions. Written informed consent was obtained from all participating women.
The first medical record transcript (DrT1) included maternal age, gestational weeks at registration, maternal body weight, height, conception and details of all previous pregnancies (vaginal delivery/caesarean delivery/miscarriage/ induced abortion/stillbirth).
The Dr0m included maternal age, gestational weeks at miscarriage and delivery, single/multiple pregnancies, live birth/stillbirth, miscarriage/induced abortion, male/female, birth weight, vaginal/caesarean delivery, pregnancy complications and perinatal outcome.
VTE was described in the Dr0m and in the third medical record transcription (Dr1m).
Exposures and Covariates
Potential exposures were compiled from medical and obstetrical histories as well as from information on gynaecological diseases, obstetric complications and lifestyle.
Potential 
Statistical Analysis
Details of potential exposures are listed in ►Supplementary Table S1 (available in the online version).
Frequencies for discrete data between VTE and each factor were counted with proportion. To compare their respective distributions, a Fisher's exact test was performed. Crude odds ratios (ORs) for all exposures were calculated and multiple logistic regression analyses were further conducted to determine what kind of exposures was predictive of VTE after controlling for maternal age, BMI, the presence/absence of IVF-ET, smoking status and income level. In case the observed number of each factor and VTE was less than 6, adjusted ORs were not calculated because of potential biases depending on the number of cases in the less frequencies.
All calculations were conducted using SPSS version 23 and 24 (IBM Corp., Japan), and a p-value of < 0.05 was regarded as statistically significant.
Results
The frequency of VTE was 7.5 per 10,000 pregnancies (77 of 103,070) during the pregnancy and post-partum period. The presence/absence of VTE according to each factor is shown in ►Tables 1 and 2. Age, BMI, the presence of IVF-ET, smoking status and income level were significantly associated with VTE.
After the adjustment of multiple covariates for each factor, endometriosis and recurrent pregnancy loss (RPL) were judged to be novel independent predictors for VTE (►Table 3). Adjusted ORs were as follows: 2.70 (95% confidence interval [CI], 1.21-6.00) for endometriosis and 6.13 (2.48-15.16) for RPL. There was no statistically significant risk related to any of the listed medical histories or lifestyle other than those mentioned above.
Regarding pregnancy complications and outcomes, oligohydramnios might be a novel independent predictor for VTE though adjusted ORs were not shown since the number was less than 6 (►Table 4). Threatened abortion, threatened preterm birth, pre-term birth at < 37 weeks and caesarean section remained significantly associated with VTE. Adjusted ORs were as follows: 3.61 (95% CI, 2.16-6.02) for threatened abortion, 2.98 (1.83-4.86) for threatened pre-term birth, 2.64 (1.30-5.36) for pre-term birth both at < 37 weeks and 2.19 (1.32-3.63) for caesarean section.
There was no association with hyperemesis or mild hypertensive disorders of pregnancy (HDP) with VTE. The association with a history of placenta praevia, adenomyosis and PCOS, pre-term birth < 34 weeks' gestation, severe HDP, placenta praevia, abruptio placenta, multiple pregnancy and VTE were unclear in this study because the sample size was relatively small. There were no cases of VTE in patients with a history of stroke, myocardial infarction, congenital heart disease, SLE, Crohn's disease, ulcerative colitis, nephrotic syndrome or various forms of cancer.
Discussion
In the present cohort, we found endometriosis and three or more pregnancy losses as novel risk factors for VTE.
Endometriosis is characterized by endometrial-like tissue outside the uterine and is a major contributor to pelvic pain and infertility. 16 This is the first study that we know of to show that endometriosis is a VTE risk factor. In fact, there was one study in which no episode of deep vein thrombosis and VTE occurred after laparoscopic surgery in a group of 266 patients in which 21% had endometriosis. 17 Lesions and activated macrophages can secrete pro-inflammatory cytokines such as interleukin-1β, interleukin-6, interleukin-8 and tumour necrosis factor α in the peritoneal cavity of patients with endometriosis. 16 These pro-inflammatory cytokines might trigger VTE during pregnancy.
With regard to RPL, to our knowledge, this is the first study to show that a history of RPL has a direct predictive value for assessing VTE risk. Stillbirth was not included in eight women with both a history of RPL and VTE, though stillbirth is well-known to be a strong risk factor for postpartum VTE. 1 RPL and VTE are considered to be associated with acquired and inheritable thrombophilia such as AT deficiency, PC deficiency, PS deficiency and homozygous factor V (FV) Leiden. 18 Clinical criteria for anti-phospholipid syndrome (APS) include thrombosis, recurrent miscarriage, intrauterine foetal death and early-onset pre-term birth following pre-eclampsia or placental insufficiency. 19 Patients with APS received combined therapy of low dose aspirin and heparin, and this applied to 162 women in the present cohort with APS. RPL was an independent predictor when APS was used as a covariate (not shown). Recently, 472 variants in 187 genes have been reported to be associated with RPL. 20 A meta-analysis revealed a significant association between RPL and 21 variants, including loss due to thrombophilia with ORs of 0.51 to 2.37. Thrombophilia related to FV Leiden mutation, pro-thrombin mutation, Abbreviation: SFD, small for dates. a Stillbirth (! 12 weeks' gestation) and artificial abortion were excluded from analyses. b Early miscarriage (< 12 weeks' gestation) and artificial abortion were excluded from analyses. c Miscarriage and artificial abortion were excluded from analyses. d The p-value was not calculated when expected frequency is less than 1.
MTHFR and ANXA5 single-nucleotide polymorphisms is reported to be associated with RPL. 20, 21 Recent large cohort study proved that the rate of VTE within 42 days of an induced abortion was 3.0 per 10,000 women (hazard ratio, 0.16, 95% CI, 0·12-0·22) when compared with women in the live birth cohort, whose VTE rate was 18.5 per 10,000 women. 22 The risk might be due to pathologies common to RPL and VTE. The frequency of VTE was found to be 7.5 per 10,000 pregnancies in the present Japanese population registered between 2011 and 2014. It was similar to that in Caucasian population, 1 but VTE has been speculated to be less frequent in the Japanese population due to the fact that no FV Leiden and pro-thrombin mutations were found in the Japanese population. 9 The frequency of PS deficiency was higher in the Japanese population because of a domestic mutation known as PS-Tokushima (K196E) which has a frequency of 1.8%. 23 According to the old guidelines, thromboprophylaxis with the use of unfractionated heparin was speculated to be common for post-partum women with a previous episode of VTE or thrombophilia or for older obese women post-partum after a caesarean section that took place between 2011 and 2014. 8 After April 2014, thromboprophylaxis during pregnancy was introduced into the JSOG guidelines. 7 Thus, the effect of thromboprophylaxis during pregnancy might be small in this analysis, but we should consider that some portion of patients with an unexplained RPL may have received a combination of low dose aspirin and unfractionated heparin even though there was no recorded evidence. 24 Actually, 267 and 1,609 women in the two groups above received heparin and low dose aspirin in the present cohort. However, any indication of treatment after VTE, prophylaxis for VTE or prevention of APS or gestational weeks at the start of heparin therapy was not available. This is one of the limitations of this study.
Associations with pre-term birth, HDP, uterine infection, multiple pregnancies and caesarean section with VTE were reported in the previous studies. 2, 3, 5 A recent risk prediction model showed that emergency caesarean delivery, stillbirth, varicose veins, pre-eclampsia and post-partum infection were the strongest predictors of post-partum VTE. 1 A pre-conceptional history of VTE was reportedly associated with an increased risk of pre-eclampsia, stillbirth and placental abruption. 25 These might also be induced by common genetic factors. An association with oligohydramnios was not confirmed by a logistic model because of the small sample size. The major limitation was that there was no distinction made between VTE during pregnancy and that occurring post-partum. Data on gestational weeks at the VTE occurrence were also not available. This might be a reason why hyperemesis were not associated with VTE in this study. Thus, we could not dismiss these associations. The majority of women were recruited at 14 weeks' gestation, therefore, we should keep in mind that we did not cover all early miscarriages or hyperemesis.
Endometriosis and a history of RPL were found to be novel risk factors for VTE. Endometriosis and RPL affect 6 to 10% and 4.2% of women of reproductive age, respectively. 16, 26 Consequently, we should pay careful attention to novel predictors, such as endometriosis and RPL, to prevent VTE in pregnant women. 
